Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 112,640

Document Document Title
WO/2016/049881A1
Provided are a conotoxin polypeptide κ-CPTx-bt104, a method for preparation thereof, and an application thereof. The conotoxin polypeptide consists of 11 amino acids, has a molecular weight of 1313.47 daltons, and has the full sequence ...  
WO/2016/049873A1
Provided are a conotoxin polypeptide κ-CPTx-bt103, a method for preparation thereof, and an application thereof. The conotoxin polypeptide consists of 29 amino acids, has a molecular weight of 3141.43 daltons, and has the full sequence ...  
WO/2016/052617A1
The present invention addresses the problem of providing a nalfurafine-containing preparation for topical application that has high drug stability in the preparation and excellent drug transfer properties from the preparation to a living...  
WO/2016/050160A1
Provided is a paliperidone oral controlled-release tablet, comprising: a single-layer tablet core containing paliperidone, a first coating layer and a second coating layer coating the single-layer tablet core to control release of medica...  
WO/2016/054475A1
The instant disclosure features, among other things, compositions and methods for treating an autism spectrum disorder in a human. The compositions comprise an effective amount of: (1) an isothiocyanate (e.g., sulforaphane or a derivativ...  
WO/2016/051195A1
The present invention is directed to the treatment of small fibre neuropathy comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmace...  
WO/2016/050203A1
A use of a casein kinase 2 inhibitor in preparing a pharmaceutical composition for enhancing the expression of type I interferon and/or a type I interferon-induced gene or a protein thereof; and/or in preparing a pharmaceutical compositi...  
WO/2016/051181A1
This invention relates to novel compounds of formula (I) wherein wherein Ά' is a 5 or 6 membered aryl or heteroaryl group, unsubstituted or substituted with 1, 2 or 3 groups as defined in claim 1; X is a bond or -(CRA1R81)n- (wherein n ...  
WO/2016/052522A1
The purpose of the present invention is to provide a method for preventing the degeneration of ropinirole in a ropinirole-containing preparation for percutaneous administration. A preparation for percutaneous administration, said prepara...  
WO/2016/053946A1
Provided are methods for reducing the progression of cognitive decline in a post¬ menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.  
WO/2016/049869A1
Disclosed are a conotoxin polypeptide κ-CPTx-bt102, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the present invention consists of 15 amino acids, has a molecular weight of 1660.61 daltons, ...  
WO/2016/053767A1
The present invention provides four crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an Aβ pa...  
WO/2016/051799A1
Provided is a tau aggregation inhibitor which is capable of sufficiently suppressing tau aggregation in cells. The present invention is a compound represented by formula (I) or a salt thereof. This compound is used for at least one appli...  
WO/2016/047638A1
Provided is: a cyclic peptide derivative which is derived from Paecilomyces tenuipes having an astrocyte proliferative activity; or a salt thereof.  
WO/2016/047924A3
The present invention relates to a fluorescent-labeled novel dieckol derivative.  
WO/2016/046638A3
The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-meth ylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vo...  
WO/2016/046162A1
The invention relates to pharmaceutical compositions comprising proline or proline derivatives and their use in the treatment of dementia, Alzheimer's and neurodegenerative diseases.  
WO/2016/044929A1
The present relates to the use of miRNA-132/212 mimics or activators comprising a doubled stranded ribonucleic acid molecule comprising a seed region sequence of miRNA-132 or miRNA-212, a spacer, a stabilizing sequence, and a carrier for...  
WO/2016/047678A1
 The present invention provides an agent for the prevention or treatment of autoimmune disease, inflammatory disease (especially inflammatory skin disease) (for example, systemic lupus erythematosus, inflammatory bowel disease, psorias...  
WO/2016/046374A1
The invention relates to methylphenidate or to a physiologically acceptable salt thereof for use in the treatment of anorexia nervosa. The invention also relates to a corresponding pharmaceutical composition.  
WO/2016/048058A1
The present invention is characterized in that racemic or optically active D- or L-α―glycerophosphoryl choline solids are prepared from liquid type racemic or optically active D- or L-α―glycerophosphoryl choline using an organic so...  
WO/2016/046817A1
A composition-of-matter is provided. The present composition includes dietary supplements capable of reducing or reversing the negative effects of alcohol on motor and cognition, dietary supplements having anti-gastroparesis, antiemetic,...  
WO/2016/049355A1
Aqueous pharmaceutical formulations, for parenteral administration, comprising peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof wherein the peptidomimetic macrocycle binds to MDM2 and/or MDMX proteins are disclosed...  
WO/2016/046835A1
The invention relates to the compounds of formula I and formula laor its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of f...  
WO/2016/046669A3
The invention relates to the compounds and compositions of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions...  
WO/2016/046673A1
The compositions and compounds of formula I which includes a salt of duloxetine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutic...  
WO/2016/047924A2
The present invention relates to a fluorescent-labeled novel dieckol derivative.  
WO/2016/046404A1
The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the compositions containing ...  
WO/2016/047677A1
[Problem] To provide a method so as to directly link phosphoethanolamine (PEA), which is a biomarker for depression, to a treatment for the same. [Solution] This method for predicting depression treatment drug alternatives includes the s...  
WO/2016/042451A1
The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein f...  
WO/2016/043583A1
Anxiety is reduced in an infant that receives breast milk from a mother that has ingested non-digestible oligosaccharide.  
WO/2016/042413A1
Disclosed herein are compositions that are useful in effecting the transdermal delivery of active agents such as opipramol. More particularly, the disclosed transdermal compositions include an active agent; one or more plasticizers; one ...  
WO/2016/042172A1
A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful for use in the treatment of cancer, an inflammatory disorder,an autoimmunity disorder or a neurodegenerative disorder.  
WO/2016/044323A1
Disclosed are chemical entities of formula I: [INSERT CHEMICAL FORMULA HERE] wherein X, Y, Z, R1, R3, R4, R5 and R6 are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions compri...  
WO/2016/041489A1
Disclosed are a compound represented by general formula I and a preparation method therefor. The compound can be used as an indoleamine-2,3-dioxygenase inhibitor to prepare medicines for preventing and/or treating indoleamine-2,3-dioxyge...  
WO/2016/044150A1
The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and / or for the treatment and / or pre...  
WO/2016/044386A1
formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, R1 and R2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by vo...  
WO/2016/041618A1
The present invention relates to substituted indazoles and related heterocycles. These compounds are useful for the prevention and/or treatment of hyperproliferative, inflammatory and degenerative disorders and diseases. Thus, this inven...  
WO/2016/044331A1
Disclosed herein are compounds of Formulae (I) and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.  
WO/2016/043996A1
The present invention provides a compound of Formula I: which is crystalline. The compound of Formula (I) is useful in the treatment of Akzheimer's disease (BACE imnhibitor).  
WO/2016/042775A1
Disclosed are compounds useful as inhibitors of phosphodiesterase 1 (PDE1), compositions thereof, and methods of using the same.  
WO/2016/042194A1
The invention relates to substituted heterocyclic indole derivatives of formula (I), which act as activators of the AMP-activated protein kinase (AMPK) and to the use thereof for the treatment and prevention of diseases or disorders regu...  
WO/2016/041192A1
Disclosed is a use of ligustilide, comprising a use of ligustilide to improve a therapeutic benefit of a stem cell, and a use of ligustilide and a stem cell treated therewith in a stem cell treatment. Treating the stem cell via the ligus...  
WO/2016/044770A1
Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. P...  
WO/2016/044314A1
Disclosed herein are novel drug combinations comprising a glutathione peroxidase (GPx) mimic compound and an antipsychotic agent, pharmaceutical compositions comprising one or more of such combinations, methods of preparing pharmaceutica...  
WO/2016/044131A1
This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutic...  
WO/2016/044447A1
There are described imidazole and pyrazole derivatives which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorder...  
WO/2016/042453A1
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibiti...  
WO/2016/044299A1
Extracts of plants of the Lamiaceae family, including the Mentha genus, are shown to have a positive impact on overall cognitive health, including improvements in memory, reasoning, attention/concentration, planning, mood, sleep and asso...  
WO/2016/042452A1
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibiti...  

Matches 551 - 600 out of 112,640